Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability-Reference-Cited by-同舟云学术

Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability

Published:2021-10-18 Issue:11 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Espinel-Ingroff A.¹^ORCID,Sasso M.²^ORCID,Turnidge J.³^ORCID,Arendrup M.⁴^ORCID,Botterel F.⁵,Bourgeois N.⁶,Bouteille B.⁷,Canton E.⁸,Cassaing S.⁹,Dannaoui E.¹⁰^ORCID,Dehais M.¹¹,Delhaes L.¹²,Dupont D.¹³,Fekkar A.¹⁴^ORCID,Fuller J.¹⁵,Garcia-Effron G.¹⁶,Garcia J.¹⁷,Gonzalez G. M.¹⁸,Govender N. P.¹⁹^ORCID,Guegan H.²⁰,Guinea J.²¹^ORCID,Houzé S.²²,Lass-Flörl C.²³^ORCID,Pelaez T.²⁴,Forastiero A.²⁵,Lackner M.²³,Magobo R.¹⁹

Affiliation:

1. VCU Medical Center, Richmond, Virginia, USA

2. MIVEGEC, Université, Montpellier, CHU de Nîmes, CNRS, IRD, Montpellier, France

3. Adelaide Medical School and School of Biological Sciences, University of Adelaide, Adelaide, Australia

4. Unit of Mycology, Department of Microbiological Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark

5. Unité de Parasitologie-Mycologie, CHU Henri Mondor, APHP, Paris, France

6. MIVEGEC, Université Montpellier, CHU de Montpellier, CNRS, IRD, Montpellier, France

7. Service de Parasitologie-Mycologie, CHU Limoges, Limoges, France

8. Grupo Infección Grave, Instituto Investigación Sanitaria La Fe, Valencia, Spain

9. Service de Parasitologie-Mycologie, CHU Toulouse, Université Paul Sabatier, Toulouse, France

10. Laboratoire de Parasitologie-Mycologie, Département de Microbiologie, Université de Paris, Faculté de Médecine, APHP, Hôpital Européen Georges Pompidou, Paris, France

11. Laboratoire de Parasitologie Mycologie, Rouen, France

12. Service de Parasitologie-Mycologie, CHU Bordeaux, France

13. Hospices Civils de Lyon, Institut des Agents Infectieux, Parasitologie-Mycologie Médicale, Université Lyon 1, Lyon, France

14. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie-Mycologie, Paris, France

15. Western University, Ontario, Canada

16. Laboratorio de Micología y Diagnóstico Molecular–CONICET, Cátedra de Parasitología y Micología, Fac. Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina

17. Hospital Universitario La Paz, Madrid, Spain

18. Universidad Autónoma de Nuevo León, Monterrey, Mexico

19. National Institute for Communicable Diseases, a Division of the National Health Laboratory Service and Faculty of Health Sciences University of Witwatersrand, Johannesburg, South Africa

20. Univ Rennes, CHU, Inserm, Irset (Institut de Recherche en Santé, Environnement et Travail)–UMR_S 1085, Rennes, France

21. Servicio de Microbiología Clínica y Enfermedades Infecciosas-VIH, Hospital General Universitario Gregorio Marañon and Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

22. Université de Paris, UMR 261 MERIT, IRD, Service de Parasitologie, AP-HP, Hôpital Bichat, Paris, France

23. Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria

24. Hospital Universitario Central de Asturias, Fundación para la Investigación Biosanitaria del Principado de Asturias, Oviedo, Spain

25. Servicio de Micologia, Laboratorio de Microbiologia, Hospital Britanico, Buenos Aires, Argentina

Abstract

Susceptibility testing is an important tool in the clinical setting; its utility is based on the availability of categorical endpoints, breakpoints (BPs), or epidemiological cutoff values (ECVs/ECOFFs). CLSI and EUCAST have developed antifungal susceptibility testing, BPs, and ECVs for some fungal species.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01093-21

Reference40 articles.

1. Drug resistance and tolerance in fungi

2. Invasive candidiasis

3. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

4. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

5. ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt;Current Microbiology;2023-10-05

2. Molecular Characterization and Sterol Profiles Identify Nonsynonymous Mutations in ERG2 as a Major Mechanism Conferring Reduced Susceptibility to Amphotericin B in Candida kefyr;Microbiology Spectrum;2023-08-17

3. Gradient concentration strip–specific epidemiological cut-off values of antifungal drugs in various yeast species and five prevalent Aspergillus species complexes;Clinical Microbiology and Infection;2023-05

4. Hospital Clonal Outbreak of Fluconazole-Resistant Candida parapsilosis Harboring the Y132F ERG11p Substitution in a French Intensive Care Unit;Antimicrobial Agents and Chemotherapy;2023-02-28

5. Acquired fluconazole resistance and genetic clustering in Diutina (Candida) catenulata from clinical samples;Clinical Microbiology and Infection;2023-02